Condition: Ewing Sarcoma · Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.
This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.
This description comes directly from the study's public registry record.
Xin Ni · 010-88324973 · nixin@bch.com.cn
Huanmin Wang · 010-88324973 · wanghuanmin@bch.com.cn
Always discuss trial participation with your own doctor first.
| Beijing Children's Hospital Affiliated to Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06564272